Nancy Andrews Sells 573 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director Nancy Andrews sold 573 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director directly owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Charles River Laboratories International Trading Up 1.3%

Shares of Charles River Laboratories International stock opened at $295.23 on Friday. The company’s fifty day simple moving average is $234.99 and its 200-day simple moving average is $193.86. The stock has a market capitalization of $14.09 billion, a PE ratio of -60.87, a P/E/G ratio of 3.02 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $299.32. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRL. Morgan Stanley boosted their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a report on Monday, August 10th. TD Cowen upped their price target on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Mizuho set a $264.00 price objective on shares of Charles River Laboratories International in a research note on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $255.65.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration
• Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers
• Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity
• Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook
• Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale
• Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in CRL. Vanguard Group Inc. raised its holdings in shares of Charles River Laboratories International by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp increased its position in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after purchasing an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after purchasing an additional 210,260 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after purchasing an additional 9,756 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.